Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
Tags:
Funding Politics Products

2 strengths of cefalexin among first 9 price concessions for November

  • News

The Department of Health and Social Care and the National Assembly for Wales have agreed concessionary prices for the following nine items for November 2019 prescriptions.

Drug
Strength
Form
Price
Alverine
60mg
capsules (100)
£9.25
Cefalexin
125mg/5ml
oral suspension (100ml)
£1.95
Cefalexin
250mg/5ml
oral suspension (100ml)
£2.25
Cyclizine
50mg/1ml
solution for injection ampoules (5)
£12.56
Hydroxyzine
25mg
tablets (28)
£1.02
Lamotrigine
100mg
sugar-free dispersible tablets (56)
£9.99
Meloxicam
7.5mg
tablets (30)
£1.91
Orlistat
120mg
capsules (84)
£28.49
Venlafaxine
75mg
tablets (56)
£4.96
Table

View full table

Do these prices reflect what you have paid in November so far?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Tags:
Funding Politics Products
Latest News & Analysis

GPhC to 'assess' pharmacy technician minimum training levels

£5m retained margin uplift ‘approved’ in Northern Ireland

Revealed: London pharmacies will offer children’s MMR jabs following case surge

Will expanding access to naloxone OTC be the right move?

See All
UsernamePublicRestriction

Register

CD006208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By